ClinicalTrials.gg
CompletedNCT05074498Updated Nov 18, 2023Results posted

Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease

A Phase 1/2 interventional study of TB006 and Placebo in Alzheimer's Disease, sponsored by TrueBinding, Inc.. Completed at 18 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by TrueBinding, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
520th of 1,609
154 · median 73
Started
2021
with 144 others
Phase 1/2
67 of 1,940
17 open now
Registered
1,371st of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 520th largest by enrollment of the 1,609 interventional ones that give a count, is one of 145 that started in 2021, is one of 67 in phase 1/2, and was the 1,371st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

Part 1 of this study will be conducted to determine the safety, tolerability, and pharmacokinetic (PK) profile of multiple doses of TB006, as well as the maximum tolerated dose of TB006, and to assess the immunogenicity of TB006 (production of anti-TB006 antibody). Part 2 of this study will be conducted to determine the clinical efficacy of TB006 in participants with mild to severe Alzheimer's Disease.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • TB006
  • pharmacokinetics
  • pharmacodynamics
  • immunogenicity
  • mild to severe Alzheimer's Disease
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight of ≥ 50 kilograms (kg) and (BMI) between 18 and 35 kg/meters squared (m\^2), inclusive
  • (MMSE) score of 24 or less
  • Must be ambulatory
  • Clinical diagnosis of Alzheimer's Disease (AD) consistent with the following:

    1. Probable AD, according to National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
    2. Meets the , Fifth Edition (DSM-5) - Criteria for Major Neurocognitive Disorder (previously dementia)
  • Participants or caregiver has the ability to understand the purpose and risks of the study and provide signed and dated which includes compliance with the requirements and restrictions listed in the inform consent form (ICF) and in this protocol. Participants whose caregiver signs the informed consent must provide their assent.

Exclusion criteria

Exclusion Criteria:

  • Any medical or neurological condition other than AD that in the opinion of the investigator could be a contributing cause of the participant's dementia (e.g., medication use, vitamin B12 deficiency, abnormal thyroid function, stroke or other cerebrovascular condition, diffuse Lewy body disease, head trauma)
  • History within the past 6 months or evidence of psychiatric illness (e.g., major depression, schizophrenia, or bipolar affective disorder)
  • Diagnosis of a dementia-related central nervous system (CNS) disease other than AD (e.g., Parkinson's Disease, Huntington's Disease, frontotemporal dementia, multi-infarct dementia, dementia with Lewy bodies, normal pressure hydrocephalus)
  • Identification of other known cause of dementia or any other clinically significant contributing co-morbid pathologies at screening magnetic resonance imaging (MRI), in the opinion of the investigator
  • Participation in any other drug, biologic, device, or clinical study or treatment with any drug or approved therapy for investigational use within 30 days (or 5 half lives, whichever is longer) prior to screening, and/or participation in any other clinical study involving experimental medications for AD within the 60 days (or 5 half lives, whichever is longer) prior to screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Part 1: TB006

    Participants will be randomized to 1 of 3 ascending dose groups to receive a total of 5 once-weekly doses of TB006, infused over 1 hour.

    Drug: TB006

  • Placebo comparator
    Part 1: Placebo

    Participants will be randomized to receive 5 once-weekly doses of matching placebo.

    Drug: Placebo

  • Experimental
    Part 2: TB006

    Participants will receive the highest safe and well-tolerated dose identified in Part 1, infused over 1 hour. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).

    Drug: TB006

  • Placebo comparator
    Part 2: Placebo

    Participants will be randomized to receive matching placebo. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).

    Drug: Placebo

Interventions

  • DrugTB006

    intravenous infusion

  • DrugPlacebo

    intravenous infusion

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.

    Time frame: Up to Day 104

  2. Part 1: Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatine Kinase (CK)

    Blood samples were collected for analysis of following clinical chemistry parameters including ALT, ALP, AST and CK. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  3. Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein

    Blood samples were collected for analysis of following clinical chemistry parameters including albumin and protein. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  4. Part 1: Change From Baseline in Chemistry Parameters: Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL (High Density Lipoprotein) Cholesterol, LDL (Low Density Lipoprotein) Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen

    Blood samples were collected for analysis of following clinical chemistry parameters including Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  5. Part 1: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C

    Blood samples were collected for analysis of following clinical chemistry parameters including Hemoglobin A1C. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  6. Part 1: Change From Baseline in Clinical Chemistry Parameters: Potassium and Sodium

    Blood samples were collected for analysis of following clinical chemistry parameters including Potassium and Sodium. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  7. Part 1: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin

    Blood samples were collected for analysis of following clinical chemistry parameters including Thyrotropin. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  8. Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets

    Blood samples were collected for analysis of following hematology parameters including Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  9. Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Hemoglobin (Ery. MCH)

    Blood samples were collected for analysis of following hematology parameter: Ery. MCH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  10. Part 1: Change From Baseline in Hematology Parameter: Hematocrit

    Blood samples were collected for analysis of following hematology parameter: Hematocrit. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  11. Part 1: Change From Baseline in Hematology Parameter: Erythrocytes and Reticulocytes

    Blood samples were collected for analysis of following hematology parameter: Erythrocytes and Reticulocytes. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  12. Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Volume (Ery. MCV)

    Blood samples were collected for analysis of following hematology parameter: Ery. MCV. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  13. Part 1: Change From Baseline in Hematology Parameter: Hemoglobin

    Blood samples were collected for analysis of following hematology parameter: Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  14. Part 1: Change From Baseline in Urine Potential of Hydrogen (pH)

    Urine samples were collected for analysis of Urine pH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  15. Part 1: Change From Baseline in Urine Specific Gravity

    Urine samples were collected for analysis of Urine specific gravity. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  16. Part 1: Change From Baseline in Urobilinogen

    Urine samples were collected for analysis of Urobilinogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  17. Part 1: Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

    Vital signs including DBP and SBP was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

    Time frame: Baseline and Up to Day 104

  18. Part 1: Change From Baseline in Respiratory Rate

    Vital signs including respiratory rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

    Time frame: Baseline and Up to Day 104

  19. Part 1: Change From Baseline in Temperature

    Vital signs including temperature was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

    Time frame: Baseline and Up to Day 104

  20. Part 1: Change From Baseline in Heart Rate

    Vital signs including heart rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

    Time frame: Baseline and Up to Day 104

  21. Part 1: Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate

    12-lead ECG measurements was obtained using an ECG machine that automatically calculates the heart rate. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value value.

    Time frame: Baseline and Up to Day 104

  22. Part 1: Change From Baseline in ECG Parameters

    12-lead ECG measurements was obtained using an ECG machine that automatically calculates the PR interval, QRS duration, QT interval and QT Corrected using Bazett's formula (QTcB). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

    Time frame: Baseline and Up to Day 104

  23. Part 1: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is an interview-based instrument to systematically assess suicidal ideation and suicidal behavior. Number of participants that have an affirmative response to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 5 items for suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide) were reported. The total score ranges from 0 (no ideation present) to 5 (active suicidal ideation with specific plan and intent); higher scores indicate worse symptoms.

    Time frame: Up to Day 104

  24. Part 1: Number of Participants With Clinically Significant Physical Examination Findings

    A complete physical examination included, at a minimum, assessment of the Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.

    Time frame: Up to Day 104

  25. Part 1: Number of Participants With Clinically Significant Neurological Examination Findings

    The neurological examination assessed mental status, motor and sensory skills, hearing and speech, vision, coordination, and balance. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.

    Time frame: Up to Day 104

  26. Part 1: Dose Normalized Area Under the Concentration Time Curve Over a Dosing Interval (AUCtau) of TB006

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis. AUCtau normalized to the actual administered dose is presented. The AUCtau was divided by the actual dose strength to get the normalized area under the concentration-time curve.

    Time frame: Day 1 and Day 29

  27. Part 1: Time at Which Maximum Plasma Concentration Occurs (Tmax) of TB006

    Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

    Time frame: At Days 1, 8 and 29

  28. Part 1: Dose Normalized Maximum Observed Plasma Concentration (Cmax) of TB006

    Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis. Cmax normalized to the actual administered dose is presented. The Cmax was divided by the actual dose strength to get the normalized maximum observed plasma concentration.

    Time frame: At Days 1, 8 and 29

  29. Part 1: Concentration at the End of a Dosing Interval (Ctrough) of TB006

    Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

    Time frame: Day 8 and Day 29

  30. Part 1: Terminal Elimination Phase Half-life (t1/2) of TB006

    Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

    Time frame: At Day 29

  31. Part 1: Total Clearance (CL) of TB006

    Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

    Time frame: At Day 29

  32. Part 1: Volume of Distribution (Vd) of TB006

    Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

    Time frame: At Day 29

  33. Part 1: Number of Participants With Anti-TB006 Antibodies (Immunogenicity of TB006)

    Plasma samples were collected at indicated time points for the determination of anti-TB006 antibodies. Plasma samples were screened for antibodies binding to TB006 and the titer of confirmed positive samples has been reported.

    Time frame: Day 1 (Predose), Day 8 (Predose), Day 36 and Day 104

  34. Part 2: Change From Baseline Through Day 104 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score

    The Clinical Dementia Rating was obtained through semi-structured interviews of participants and informants, and cognitive functioning was rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain was rated on a five-point scale of functioning as follows: 0: no impairment; 0.5: questionable impairment; 1: mild impairment; 2: moderate impairment; and 3: severe impairment. The Clinical Dementia Rating Scale - Sum of Boxes was based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes, and higher total scores represent worse outcomes. Baseline was defined as the last available value prior to the subject receiving the first study drug infusion on Day 1. Change from Baseline value was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline through Day 104

Secondary outcomes

  1. Part 2: Change From Baseline Through Day 36 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score

    The Clinical Dementia Rating was obtained through semi-structured interviews of participants and informants, and cognitive functioning was rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain was rated on a five-point scale of functioning as follows: 0: no impairment; 0.5: questionable impairment; 1: mild impairment; 2: moderate impairment; and 3: severe impairment. The Clinical Dementia Rating Scale - Sum of Boxes was based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes, and higher total scores represent worse outcomes. Baseline was defined as the last available value prior to the subject receiving the first study drug infusion on Day 1. Change from Baseline value was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline through Day 36

  2. Part 2: Percentage of Responders on the Clinical Dementia Rating Scale - Sum of Boxes

    The Clinical Dementia Rating is obtained through semi-structured interviews of participants and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment. The Clinical Dementia Rating Scale - Sum of Boxes is based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes, and higher total scores represent worse outcomes. A responder was defined as a participant with at least 1 point improvement from Baseline on the Sum of Boxes score. Percentage of responders on the Clinical Dementia Rating Scale - Sum of Boxes has been presented.

    Time frame: At Days 36 and 104

  3. Part 2: Change From Baseline on Mini-Mental State Examination (MMSE) Score

    The MMSE was used to measure cognitive impairment. The MMSE can evaluate overall cognitive function, and is widely used for the assessment of cognitive impairment in dementia participants. The questionnaire consists of 11 items, and each item aims to evaluate different cognitive domains such as orientation, memory, attention, and construction. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from Baseline. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and at Days 36 and 104

  4. Part 2: Change From Baseline on the Neuropsychiatric Inventory (NPI) Score

    The NPI was a questionnaire that quantified psychiatric symptoms and behavioral disorders in dementia. A total of 12 items (the original NPI-10 consisting of 10 behavioral domains: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor behavior, The NPI total score was calculated by adding the scores of the domains (each domain scores ranges from 0 to 12). The NPI total score ranges from 0 to 120 with higher scores indicating greater behavioral impairment. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and at Days 36 and 104

  5. Part 2: Number of Participants With AEs and SAEs

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.

    Time frame: Up to Day 104

  6. Part 2: Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and CK

    Blood samples were collected for analysis of following clinical chemistry parameters including ALT, ALP, AST and CK. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  7. Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein

    Blood samples were collected for analysis of following clinical chemistry parameters including albumin and protein. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  8. Part 2: Change From Baseline in Chemistry Parameters: Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen

    Blood samples were collected for analysis of following clinical chemistry parameters including Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  9. Part 2: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C

    Blood samples were collected for analysis of following clinical chemistry parameter including Hemoglobin A1C. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  10. Part 2: Change From Baseline in Clinical Chemistry Parameters: Potassium and Sodium

    Blood samples were collected for analysis of following clinical chemistry parameters including Potassium and Sodium. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  11. Part 2: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin

    Blood samples were collected for analysis of following clinical chemistry parameter including Thyrotropin. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  12. Part 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets

    Blood samples were collected for analysis of following hematology parameters including Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  13. Part 2: Change From Baseline in Hematology Parameter: Ery. MCH

    Blood samples were collected for analysis of following hematology parameter: Ery. MCH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  14. Part 2: Change From Baseline in Hematology Parameter: Ery. MCV

    Blood samples were collected for analysis of following hematology parameter: Ery. MCV. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  15. Part 2: Change From Baseline in Hematology Parameter: Erythrocytes and Reticulocytes

    Blood samples were collected for analysis of following hematology parameter: Erythrocytes and Reticulocytes. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  16. Part 2: Change From Baseline in Hematology Parameter: Hematocrit

    Blood samples were collected for analysis of following hematology parameter: Hematocrit. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  17. Part 2: Change From Baseline in Hematology Parameter: Hemoglobin

    Blood samples were collected for analysis of following hematology parameter: Hemoglobin. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  18. Part 2: Change From Baseline in Urine pH

    Urine samples were collected for analysis of Urine pH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  19. Part 2: Change From Baseline in Urine Specific Gravity

    Urine samples were collected for analysis of Urine specific gravity. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  20. Part 2: Change From Baseline in Urobilinogen

    Urine samples were collected for analysis of Urobilinogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

    Time frame: Baseline and up to Day 104

  21. Part 2: Change From Baseline in DBP and SBP

    Vital signs including DBP and SBP was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

    Time frame: Baseline and Up to Day 104

  22. Part 2: Change From Baseline in Respiratory Rate

    Vital signs including respiratory rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

    Time frame: Baseline and Up to Day 104

  23. Part 2: Change From Baseline in Temperature

    Vital signs including temperature was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

    Time frame: Baseline and Up to Day 104

  24. Part 2: Change From Baseline in Heart Rate

    Vital signs including heart rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

    Time frame: Baseline and Up to Day 104

  25. Part 2: Change From Baseline in ECG Parameters

    12-lead ECG measurements was obtained using an ECG machine that automatically calculates the PR interval, QRS duration, QT interval and QTcB. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

    Time frame: Baseline and Up to Day 104

  26. Part 2: Change From Baseline in ECG Mean Heart Rate

    12-lead ECG measurements was obtained using an ECG machine that automatically calculates the heart rate. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

    Time frame: Baseline and Up to Day 104

  27. Part 2: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS

    The C-SSRS is an interview-based instrument to systematically assess suicidal ideation and suicidal behavior. Number of participants that have an affirmative response to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 5 items for suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide) were reported. The total score ranges from 0 (no ideation present) to 5 (active suicidal ideation with specific plan and intent); higher scores indicate worse symptoms.

    Time frame: Up to Day 104

  28. Part 2: Number of Participants With Clinically Significant Physical Examination Findings

    A complete physical examination included, at a minimum, assessment of the Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.

    Time frame: Up to Day 104

  29. Part 2: Number of Participants With Clinically Significant Neurological Examination Findings

    The neurological examination assessed mental status, motor and sensory skills, hearing and speech, vision, coordination, and balance. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.

    Time frame: Up to Day 104

  30. Part 2: Ctrough of TB006

    Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

    Time frame: Day 29

  31. Part 2: t1/2 of TB006

    Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

    Time frame: Day 29

  32. Part 2: Cmax of TB006

    Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

    Time frame: Day 1 and Day 29

07

Results

Posted Nov 18, 2023

Participant flow

This was a multi-center study conducted at various centers across United States (US).

Part 1 (Upto Day 104)
Participant flow — Part 1 (Upto Day 104)
MilestonePart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: PlaceboPart 2: TB006 1000 mg qwPart 2: Placebo
Started766600
Completed666500
Not completed100100
Withdrew: Lost to follow-up000100
Withdrew: Other100000
Part 2 (Upto Day 104)
Participant flow — Part 2 (Upto Day 104)
MilestonePart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: PlaceboPart 2: TB006 1000 mg qwPart 2: Placebo
Started00006366
Completed00005864
Not completed000052
Withdrew: Withdrawal by subject000020
Withdrew: Death000010
Withdrew: Lost to follow-up000012
Withdrew: Other000010

Outcome measures

PrimaryPart 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.

Time frame:
Up to Day 104
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Any AE5412
Any SAE1000
PrimaryPart 1: Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatine Kinase (CK)

Blood samples were collected for analysis of following clinical chemistry parameters including ALT, ALP, AST and CK. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · International Units per Liter
Part 1: Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatine Kinase (CK)
International Units per LiterPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
ALT-1.7 ± 2.21-5.5 ± 5.32-0.7 ± 10.335.4 ± 14.79
ALP-0.6 ± 9.11-4.0 ± 5.59-2.2 ± 10.059.0 ± 15.98
AST-0.1 ± 2.27-3.8 ± 5.23-1.3 ± 7.613.2 ± 13.65
CK22.0 ± 39.270.5 ± 44.370.3 ± 65.56-10.4 ± 14.03
PrimaryPart 1: Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein

Blood samples were collected for analysis of following clinical chemistry parameters including albumin and protein. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · grams per deciliter
Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein
grams per deciliterPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Albumin-0.14 ± 0.1990.02 ± 0.098-0.03 ± 0.367-0.04 ± 0.167
Protein-0.20 ± 0.3160.12 ± 0.183-0.05 ± 0.589-0.08 ± 0.363
PrimaryPart 1: Change From Baseline in Chemistry Parameters: Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL (High Density Lipoprotein) Cholesterol, LDL (Low Density Lipoprotein) Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen

Blood samples were collected for analysis of following clinical chemistry parameters including Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · milligrams per deciliter
Part 1: Change From Baseline in Chemistry Parameters: Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL (High Density Lipoprotein) Cholesterol, LDL (Low Density Lipoprotein) Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen
milligrams per deciliterPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Calcium-0.13 ± 0.3730.17 ± 0.280-0.02 ± 0.360-0.18 ± 0.356
Cholesterol-15.4 ± 21.62-2.7 ± 10.356.2 ± 74.37-13.4 ± 47.79
Creatinine0.047 ± 0.0810.153 ± 0.3770.108 ± 0.143-0.040 ± 0.142
Direct Bilirubin-0.007 ± 0.032-0.003 ± 0.0330.000 ± 0.020-0.022 ± 0.030
Glucose34.3 ± 55.23-15.0 ± 18.5121.3 ± 45.458.2 ± 49.94
HDL Cholesterol-3.6 ± 5.19-3.0 ± 4.650.2 ± 13.984.0 ± 17.13
LDL Cholesterol-9.0 ± 9.04-1.8 ± 9.33-3.5 ± 64.62-14.8 ± 46.23
Total Bilirubin-0.036 ± 0.093-0.005 ± 0.2270.032 ± 0.132-0.134 ± 0.225
Triglycerides-23.3 ± 69.6512.2 ± 17.7218.7 ± 104.95-23.8 ± 39.06
Urea Nitrogen-0.40 ± 2.1716.95 ± 8.2772.43 ± 3.4491.30 ± 4.266
PrimaryPart 1: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C

Blood samples were collected for analysis of following clinical chemistry parameters including Hemoglobin A1C. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · percentage of glycosylated hemoglobin
Part 1: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C
percentage of glycosylated hemoglobinPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Part 1: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C0.06 ± 0.162-0.02 ± 0.567-0.33 ± 0.625-0.14 ± 1.011
PrimaryPart 1: Change From Baseline in Clinical Chemistry Parameters: Potassium and Sodium

Blood samples were collected for analysis of following clinical chemistry parameters including Potassium and Sodium. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · Millimoles per liter
Part 1: Change From Baseline in Clinical Chemistry Parameters: Potassium and Sodium
Millimoles per literPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Potassium0.10 ± 0.476-0.15 ± 0.2880.07 ± 0.3780.02 ± 0.259
Sodium-1.0 ± 2.240.8 ± 1.72-1.2 ± 2.56-1.2 ± 2.39
PrimaryPart 1: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin

Blood samples were collected for analysis of following clinical chemistry parameters including Thyrotropin. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · micro-international units per milliliter
Part 1: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin
micro-international units per milliliterPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Part 1: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin1.209 ± 3.114-0.343 ± 0.298-0.370 ± 1.312-0.246 ± 0.372
PrimaryPart 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets

Blood samples were collected for analysis of following hematology parameters including Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · 10^3 cells per microliter
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
10^3 cells per microliterPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Basophils-0.023 ± 0.015-0.005 ± 0.0190.005 ± 0.0280.006 ± 0.013
Eosinophils0.014 ± 0.1380.003 ± 0.0680.038 ± 0.0890.030 ± 0.173
Leukocytes-0.76 ± 0.6500.00 ± 1.2920.40 ± 1.563-0.28 ± 1.092
Lymphocytes-0.264 ± 0.188-0.025 ± 0.241-0.037 ± 1.265-0.036 ± 0.250
Monocytes-0.094 ± 0.118-0.017 ± 0.1140.032 ± 0.1080.028 ± 0.062
Neutrophils-0.396 ± 0.7190.078 ± 1.1710.368 ± 0.641-0.318 ± 1.145
Platelets-9.1 ± 37.535.0 ± 37.25-9.6 ± 89.83-4.5 ± 50.16
PrimaryPart 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Hemoglobin (Ery. MCH)

Blood samples were collected for analysis of following hematology parameter: Ery. MCH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · picograms
Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Hemoglobin (Ery. MCH)
picogramsPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Hemoglobin (Ery. MCH)-0.40 ± 1.134-0.05 ± 0.5791.02 ± 3.511-0.34 ± 0.631
PrimaryPart 1: Change From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected for analysis of following hematology parameter: Hematocrit. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · Percentage
Part 1: Change From Baseline in Hematology Parameter: Hematocrit
PercentagePart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Part 1: Change From Baseline in Hematology Parameter: Hematocrit0.69 ± 2.5631.18 ± 2.1051.18 ± 7.9190.32 ± 2.493
PrimaryPart 1: Change From Baseline in Hematology Parameter: Erythrocytes and Reticulocytes

Blood samples were collected for analysis of following hematology parameter: Erythrocytes and Reticulocytes. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · 10^6 cells per microliter
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes and Reticulocytes
10^6 cells per microliterPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Erythrocytes0.039 ± 0.4010.012 ± 0.219-0.108 ± 0.6250.024 ± 0.211
Reticulocytes-0.011 ± 0.017-0.005 ± 0.004-0.008 ± 0.008-0.005 ± 0.009
PrimaryPart 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Volume (Ery. MCV)

Blood samples were collected for analysis of following hematology parameter: Ery. MCV. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · femtoliters
Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Volume (Ery. MCV)
femtolitersPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Volume (Ery. MCV)0.80 ± 1.9262.45 ± 1.3435.42 ± 5.7240.20 ± 2.699
PrimaryPart 1: Change From Baseline in Hematology Parameter: Hemoglobin

Blood samples were collected for analysis of following hematology parameter: Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · grams per deciliter
Part 1: Change From Baseline in Hematology Parameter: Hemoglobin
grams per deciliterPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Part 1: Change From Baseline in Hematology Parameter: Hemoglobin-0.06 ± 0.7790.00 ± 0.4650.08 ± 3.260-0.10 ± 0.877
PrimaryPart 1: Change From Baseline in Urine Potential of Hydrogen (pH)

Urine samples were collected for analysis of Urine pH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · potential of Hydrogen
Part 1: Change From Baseline in Urine Potential of Hydrogen (pH)
potential of HydrogenPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Part 1: Change From Baseline in Urine Potential of Hydrogen (pH)-0.36 ± 1.2150.40 ± 1.294-0.50 ± 1.612-0.80 ± 0.975
PrimaryPart 1: Change From Baseline in Urine Specific Gravity

Urine samples were collected for analysis of Urine specific gravity. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · Ratio
Part 1: Change From Baseline in Urine Specific Gravity
RatioPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Part 1: Change From Baseline in Urine Specific Gravity0.003 ± 0.0080.003 ± 0.0060.004 ± 0.0110.007 ± 0.010
PrimaryPart 1: Change From Baseline in Urobilinogen

Urine samples were collected for analysis of Urobilinogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · milligrams per deciliter
Part 1: Change From Baseline in Urobilinogen
milligrams per deciliterPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Part 1: Change From Baseline in Urobilinogen0.00 ± 0.462-0.16 ± 0.358-0.13 ± 0.6020.00 ± 0.000
PrimaryPart 1: Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

Vital signs including DBP and SBP was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

Time frame:
Baseline and Up to Day 104
Reported as:
Mean · Millimeters of mercury
Part 1: Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
Millimeters of mercuryPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
DBP-2.1 ± 12.06-2.3 ± 10.37-1.0 ± 3.03-7.2 ± 9.09
SBP-10.4 ± 13.393.5 ± 9.61-6.2 ± 13.172.2 ± 17.74
PrimaryPart 1: Change From Baseline in Respiratory Rate

Vital signs including respiratory rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

Time frame:
Baseline and Up to Day 104
Reported as:
Mean · breaths per minute
Part 1: Change From Baseline in Respiratory Rate
breaths per minutePart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Part 1: Change From Baseline in Respiratory Rate0.0 ± 0.00-0.7 ± 2.160.3 ± 1.03-0.2 ± 1.30
PrimaryPart 1: Change From Baseline in Temperature

Vital signs including temperature was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

Time frame:
Baseline and Up to Day 104
Reported as:
Mean · degrees Celsius
Part 1: Change From Baseline in Temperature
degrees CelsiusPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Part 1: Change From Baseline in Temperature0.26 ± 0.351-0.37 ± 0.350-0.03 ± 0.833-0.22 ± 0.130
PrimaryPart 1: Change From Baseline in Heart Rate

Vital signs including heart rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

Time frame:
Baseline and Up to Day 104
Reported as:
Mean · Beats per minute
Part 1: Change From Baseline in Heart Rate
Beats per minutePart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Part 1: Change From Baseline in Heart Rate-2.0 ± 8.003.3 ± 3.724.0 ± 5.73-4.2 ± 9.50
PrimaryPart 1: Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate

12-lead ECG measurements was obtained using an ECG machine that automatically calculates the heart rate. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value value.

Time frame:
Baseline and Up to Day 104
Reported as:
Mean · Beats per minute
Part 1: Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate
Beats per minutePart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Part 1: Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate-4.8 ± 5.78-0.9 ± 4.003.0 ± 3.82-3.4 ± 4.87
PrimaryPart 1: Change From Baseline in ECG Parameters

12-lead ECG measurements was obtained using an ECG machine that automatically calculates the PR interval, QRS duration, QT interval and QT Corrected using Bazett's formula (QTcB). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

Time frame:
Baseline and Up to Day 104
Reported as:
Mean · milliseconds
Part 1: Change From Baseline in ECG Parameters
millisecondsPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
PR Interval4.8 ± 10.070.7 ± 5.90-11.0 ± 14.7414.9 ± 5.16
QRS Duration0.3 ± 3.071.1 ± 5.271.0 ± 7.16-4.1 ± 13.50
QT Interval21.9 ± 12.72-2.9 ± 10.480.3 ± 9.36-5.0 ± 11.47
QTcB Interval8.1 ± 11.37-6.6 ± 12.989.9 ± 11.50-15.2 ± 4.15
PrimaryPart 1: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is an interview-based instrument to systematically assess suicidal ideation and suicidal behavior. Number of participants that have an affirmative response to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 5 items for suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide) were reported. The total score ranges from 0 (no ideation present) to 5 (active suicidal ideation with specific plan and intent); higher scores indicate worse symptoms.

Time frame:
Up to Day 104
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Wish to be dead0000
Non-specific active suicidal thoughts0000
Active suicidal ideation without any methods without intent to act0000
Active suicidal ideation with some intent to act, without specific plan0000
Active suicidal ideation with specific plan and intent0000
Any suicidal behavior0000
Actual attempt0000
Interrupted attempt0000
Aborted attempt0000
Preparatory acts or behavior0000
Most recent attempt0000
First attempt0000
Lethal attempt0000
PrimaryPart 1: Number of Participants With Clinically Significant Physical Examination Findings

A complete physical examination included, at a minimum, assessment of the Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.

Time frame:
Up to Day 104

No measurements were reported for this outcome.

PrimaryPart 1: Number of Participants With Clinically Significant Neurological Examination Findings

The neurological examination assessed mental status, motor and sensory skills, hearing and speech, vision, coordination, and balance. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.

Time frame:
Up to Day 104

No measurements were reported for this outcome.

PrimaryPart 1: Dose Normalized Area Under the Concentration Time Curve Over a Dosing Interval (AUCtau) of TB006

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis. AUCtau normalized to the actual administered dose is presented. The AUCtau was divided by the actual dose strength to get the normalized area under the concentration-time curve.

Time frame:
Day 1 and Day 29
Reported as:
Geometric mean · hours*micrograms/milliliter/milligram
Part 1: Dose Normalized Area Under the Concentration Time Curve Over a Dosing Interval (AUCtau) of TB006
hours*micrograms/milliliter/milligramPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qw
Day 139.81 ± 23.1729.87 ± 38.1511.93 ± 100.21
Day 29125.92 ± 18.01117.75 ± 24.5282.95 ± 18.18
PrimaryPart 1: Time at Which Maximum Plasma Concentration Occurs (Tmax) of TB006

Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

Time frame:
At Days 1, 8 and 29
Reported as:
Median · hours
Part 1: Time at Which Maximum Plasma Concentration Occurs (Tmax) of TB006
hoursPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qw
Day 11.12 (1.0 to 7.0)2.01 (1.1 to 5.0)2.00 (1.0 to 5.0)
Day 81.23 (1.0 to 2.0)1.60 (1.2 to 5.0)2.50 (1.1 to 5.0)
Day 292.03 (1.1 to 5.1)2.18 (1.1 to 7.0)2.00 (1.0 to 7.0)
PrimaryPart 1: Dose Normalized Maximum Observed Plasma Concentration (Cmax) of TB006

Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis. Cmax normalized to the actual administered dose is presented. The Cmax was divided by the actual dose strength to get the normalized maximum observed plasma concentration.

Time frame:
At Days 1, 8 and 29
Reported as:
Geometric mean · micrograms/milliliter/milligram
Part 1: Dose Normalized Maximum Observed Plasma Concentration (Cmax) of TB006
micrograms/milliliter/milligramPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qw
Day 10.36 ± 25.720.29 ± 36.970.07 ± 105.32
Day 80.58 ± 27.570.49 ± 26.770.30 ± 30.27
Day 290.95 ± 18.150.85 ± 22.890.61 ± 13.40
PrimaryPart 1: Concentration at the End of a Dosing Interval (Ctrough) of TB006

Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

Time frame:
Day 8 and Day 29
Reported as:
Geometric mean · micrograms per milliliter
Part 1: Concentration at the End of a Dosing Interval (Ctrough) of TB006
micrograms per milliliterPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qw
Day 825.77 ± 21.2371.44 ± 20.7568.62 ± 70.91
Day 2976.69 ± 19.62204.77 ± 20.46348.20 ± 22.34
PrimaryPart 1: Terminal Elimination Phase Half-life (t1/2) of TB006

Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

Time frame:
At Day 29
Reported as:
Geometric mean · hours
Part 1: Terminal Elimination Phase Half-life (t1/2) of TB006
hoursPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qw
Part 1: Terminal Elimination Phase Half-life (t1/2) of TB006711.49 ± 19.87757.59 ± 22.80739.50 ± 14.90
PrimaryPart 1: Total Clearance (CL) of TB006

Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

Time frame:
At Day 29
Reported as:
Geometric mean · milliliters per hour
Part 1: Total Clearance (CL) of TB006
milliliters per hourPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qw
Part 1: Total Clearance (CL) of TB0067.94 ± 17.068.49 ± 19.2712.06 ± 19.68
PrimaryPart 1: Volume of Distribution (Vd) of TB006

Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

Time frame:
At Day 29
Reported as:
Geometric mean · milliliters
Part 1: Volume of Distribution (Vd) of TB006
millilitersPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qw
Part 1: Volume of Distribution (Vd) of TB0068151.47 ± 21.389282.51 ± 28.9713617.70 ± 30.63
PrimaryPart 1: Number of Participants With Anti-TB006 Antibodies (Immunogenicity of TB006)

Plasma samples were collected at indicated time points for the determination of anti-TB006 antibodies. Plasma samples were screened for antibodies binding to TB006 and the titer of confirmed positive samples has been reported.

Time frame:
Day 1 (Predose), Day 8 (Predose), Day 36 and Day 104
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Anti-TB006 Antibodies (Immunogenicity of TB006)
ParticipantsPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: Placebo
Day 1 (Predose)0000
Day 8 (Predose)0000
Day 360000
Day 1041000
PrimaryPart 2: Change From Baseline Through Day 104 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score

The Clinical Dementia Rating was obtained through semi-structured interviews of participants and informants, and cognitive functioning was rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain was rated on a five-point scale of functioning as follows: 0: no impairment; 0.5: questionable impairment; 1: mild impairment; 2: moderate impairment; and 3: severe impairment. The Clinical Dementia Rating Scale - Sum of Boxes was based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes, and higher total scores represent worse outcomes. Baseline was defined as the last available value prior to the subject receiving the first study drug infusion on Day 1. Change from Baseline value was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline through Day 104
Reported as:
Least squares mean · Scores on a scale
Part 2: Change From Baseline Through Day 104 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score
Scores on a scalePart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline Through Day 104 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score0.01 ± 0.1470.35 ± 0.142
Statistical analysis
  • Part 2: TB006 1000 mg qw vs Part 2: Placebo · Mixed Models Analysis · p = 0.0838 · Least square mean difference: -0.35 · 95% CI -0.741 to 0.047
SecondaryPart 2: Change From Baseline Through Day 36 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score

The Clinical Dementia Rating was obtained through semi-structured interviews of participants and informants, and cognitive functioning was rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain was rated on a five-point scale of functioning as follows: 0: no impairment; 0.5: questionable impairment; 1: mild impairment; 2: moderate impairment; and 3: severe impairment. The Clinical Dementia Rating Scale - Sum of Boxes was based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes, and higher total scores represent worse outcomes. Baseline was defined as the last available value prior to the subject receiving the first study drug infusion on Day 1. Change from Baseline value was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline through Day 36
Reported as:
Least squares mean · Scores on a scale
Part 2: Change From Baseline Through Day 36 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score
Scores on a scalePart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline Through Day 36 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score-0.16 ± 0.1620.23 ± 0.157
SecondaryPart 2: Percentage of Responders on the Clinical Dementia Rating Scale - Sum of Boxes

The Clinical Dementia Rating is obtained through semi-structured interviews of participants and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment. The Clinical Dementia Rating Scale - Sum of Boxes is based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes, and higher total scores represent worse outcomes. A responder was defined as a participant with at least 1 point improvement from Baseline on the Sum of Boxes score. Percentage of responders on the Clinical Dementia Rating Scale - Sum of Boxes has been presented.

Time frame:
At Days 36 and 104
Reported as:
Number · Percentage of responders
Part 2: Percentage of Responders on the Clinical Dementia Rating Scale - Sum of Boxes
Percentage of respondersPart 2: TB006 1000 mg qwPart 2: Placebo
Day 3625.49.7
Day 10422.415.3
SecondaryPart 2: Change From Baseline on Mini-Mental State Examination (MMSE) Score

The MMSE was used to measure cognitive impairment. The MMSE can evaluate overall cognitive function, and is widely used for the assessment of cognitive impairment in dementia participants. The questionnaire consists of 11 items, and each item aims to evaluate different cognitive domains such as orientation, memory, attention, and construction. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from Baseline. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and at Days 36 and 104
Reported as:
Mean · Scores on a scale
Part 2: Change From Baseline on Mini-Mental State Examination (MMSE) Score
Scores on a scalePart 2: TB006 1000 mg qwPart 2: Placebo
Day 361.2 ± 2.590.2 ± 2.52
Day 1041.0 ± 3.100.6 ± 2.97
SecondaryPart 2: Change From Baseline on the Neuropsychiatric Inventory (NPI) Score

The NPI was a questionnaire that quantified psychiatric symptoms and behavioral disorders in dementia. A total of 12 items (the original NPI-10 consisting of 10 behavioral domains: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor behavior, The NPI total score was calculated by adding the scores of the domains (each domain scores ranges from 0 to 12). The NPI total score ranges from 0 to 120 with higher scores indicating greater behavioral impairment. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and at Days 36 and 104
Reported as:
Mean · Scores on a scale
Part 2: Change From Baseline on the Neuropsychiatric Inventory (NPI) Score
Scores on a scalePart 2: TB006 1000 mg qwPart 2: Placebo
Day 36-2.5 ± 8.10-0.8 ± 9.12
Day 104-3.5 ± 11.47-1.1 ± 6.79
SecondaryPart 2: Number of Participants With AEs and SAEs

An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.

Time frame:
Up to Day 104
Reported as:
Count of participants · Participants
Part 2: Number of Participants With AEs and SAEs
ParticipantsPart 2: TB006 1000 mg qwPart 2: Placebo
Any AE2817
Any SAE41
SecondaryPart 2: Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and CK

Blood samples were collected for analysis of following clinical chemistry parameters including ALT, ALP, AST and CK. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · International Units per Liter
Part 2: Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and CK
International Units per LiterPart 2: TB006 1000 mg qwPart 2: Placebo
ALT-0.5 ± 12.88-0.4 ± 5.40
ALP1.0 ± 12.010.0 ± 11.92
AST-0.4 ± 10.44-0.5 ± 3.58
CK-14.3 ± 77.246.3 ± 52.07
SecondaryPart 2: Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein

Blood samples were collected for analysis of following clinical chemistry parameters including albumin and protein. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · grams per deciliter
Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein
grams per deciliterPart 2: TB006 1000 mg qwPart 2: Placebo
Albumin-0.10 ± 0.300-0.01 ± 0.251
Protein-0.10 ± 0.4700.00 ± 0.404
SecondaryPart 2: Change From Baseline in Chemistry Parameters: Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen

Blood samples were collected for analysis of following clinical chemistry parameters including Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · milligrams per deciliter
Part 2: Change From Baseline in Chemistry Parameters: Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen
milligrams per deciliterPart 2: TB006 1000 mg qwPart 2: Placebo
Calcium-0.09 ± 0.437-0.11 ± 0.432
Cholesterol-5.8 ± 32.300.3 ± 28.17
Creatinine0.014 ± 0.098-0.017 ± 0.124
Direct Bilirubin0.005 ± 0.037-0.006 ± 0.030
Glucose-5.6 ± 26.98-6.3 ± 27.92
HDL Cholesterol-2.4 ± 8.49-0.3 ± 8.26
LDL Cholesterol-7.5 ± 24.64-4.6 ± 23.63
Total Bilirubin0.023 ± 0.157-0.014 ± 0.128
Triglycerides-9.2 ± 73.95-0.4 ± 46.29
Urea Nitrogen0.41 ± 3.817-1.03 ± 4.777
SecondaryPart 2: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C

Blood samples were collected for analysis of following clinical chemistry parameter including Hemoglobin A1C. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · percentage of glycosylated hemoglobin
Part 2: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C
percentage of glycosylated hemoglobinPart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C-0.06 ± 0.6380.07 ± 0.555
SecondaryPart 2: Change From Baseline in Clinical Chemistry Parameters: Potassium and Sodium

Blood samples were collected for analysis of following clinical chemistry parameters including Potassium and Sodium. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · Millimoles per liter
Part 2: Change From Baseline in Clinical Chemistry Parameters: Potassium and Sodium
Millimoles per literPart 2: TB006 1000 mg qwPart 2: Placebo
Potassium-0.14 ± 0.469-0.13 ± 0.521
Sodium-0.7 ± 2.11-0.7 ± 3.05
SecondaryPart 2: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin

Blood samples were collected for analysis of following clinical chemistry parameter including Thyrotropin. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · micro-international units per milliliter
Part 2: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin
micro-international units per milliliterPart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin-0.118 ± 0.6190.134 ± 1.000
SecondaryPart 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets

Blood samples were collected for analysis of following hematology parameters including Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · 10^3 cells per microliter
Part 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
10^3 cells per microliterPart 2: TB006 1000 mg qwPart 2: Placebo
Basophils-0.004 ± 0.027-0.002 ± 0.022
Eosinophils-0.008 ± 0.113-0.040 ± 0.130
Leukocytes-0.26 ± 1.383-0.02 ± 1.244
Lymphocytes-0.118 ± 0.392-0.053 ± 0.411
Monocytes-0.021 ± 0.1090.003 ± 0.107
Neutrophils-0.109 ± 1.2950.067 ± 1.206
Platelets-1.9 ± 32.08-12.1 ± 46.27
SecondaryPart 2: Change From Baseline in Hematology Parameter: Ery. MCH

Blood samples were collected for analysis of following hematology parameter: Ery. MCH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · picograms
Part 2: Change From Baseline in Hematology Parameter: Ery. MCH
picogramsPart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline in Hematology Parameter: Ery. MCH0.19 ± 0.7750.51 ± 1.045
SecondaryPart 2: Change From Baseline in Hematology Parameter: Ery. MCV

Blood samples were collected for analysis of following hematology parameter: Ery. MCV. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · femtoliters
Part 2: Change From Baseline in Hematology Parameter: Ery. MCV
femtolitersPart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline in Hematology Parameter: Ery. MCV1.54 ± 2.7432.04 ± 3.412
SecondaryPart 2: Change From Baseline in Hematology Parameter: Erythrocytes and Reticulocytes

Blood samples were collected for analysis of following hematology parameter: Erythrocytes and Reticulocytes. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · 10^6 cells per microliter
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes and Reticulocytes
10^6 cells per microliterPart 2: TB006 1000 mg qwPart 2: Placebo
Erythrocytes-0.028 ± 0.2690.024 ± 0.228
Reticulocytes0.001 ± 0.012-0.003 ± 0.012
SecondaryPart 2: Change From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected for analysis of following hematology parameter: Hematocrit. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · Percentage
Part 2: Change From Baseline in Hematology Parameter: Hematocrit
PercentagePart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline in Hematology Parameter: Hematocrit0.41 ± 2.7351.11 ± 2.403
SecondaryPart 2: Change From Baseline in Hematology Parameter: Hemoglobin

Blood samples were collected for analysis of following hematology parameter: Hemoglobin. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · grams per deciliter
Part 2: Change From Baseline in Hematology Parameter: Hemoglobin
grams per deciliterPart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline in Hematology Parameter: Hemoglobin0.00 ± 0.7660.29 ± 0.827
SecondaryPart 2: Change From Baseline in Urine pH

Urine samples were collected for analysis of Urine pH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · potential of Hydrogen
Part 2: Change From Baseline in Urine pH
potential of HydrogenPart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline in Urine pH-0.13 ± 0.7880.18 ± 0.791
SecondaryPart 2: Change From Baseline in Urine Specific Gravity

Urine samples were collected for analysis of Urine specific gravity. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · Ratio
Part 2: Change From Baseline in Urine Specific Gravity
RatioPart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline in Urine Specific Gravity0.002 ± 0.0100.001 ± 0.008
SecondaryPart 2: Change From Baseline in Urobilinogen

Urine samples were collected for analysis of Urobilinogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

Time frame:
Baseline and up to Day 104
Reported as:
Mean · milligrams per deciliter
Part 2: Change From Baseline in Urobilinogen
milligrams per deciliterPart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline in Urobilinogen0.07 ± 0.3130.05 ± 0.354
SecondaryPart 2: Change From Baseline in DBP and SBP

Vital signs including DBP and SBP was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

Time frame:
Baseline and Up to Day 104
Reported as:
Mean · Millimeters of mercury
Part 2: Change From Baseline in DBP and SBP
Millimeters of mercuryPart 2: TB006 1000 mg qwPart 2: Placebo
DBP0.8 ± 6.420.7 ± 9.48
SBP1.4 ± 15.020.0 ± 15.57
SecondaryPart 2: Change From Baseline in Respiratory Rate

Vital signs including respiratory rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

Time frame:
Baseline and Up to Day 104
Reported as:
Mean · breaths per minute
Part 2: Change From Baseline in Respiratory Rate
breaths per minutePart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline in Respiratory Rate0.1 ± 0.970.2 ± 0.97
SecondaryPart 2: Change From Baseline in Temperature

Vital signs including temperature was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

Time frame:
Baseline and Up to Day 104
Reported as:
Mean · degrees Celsius
Part 2: Change From Baseline in Temperature
degrees CelsiusPart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline in Temperature0.01 ± 0.489-0.03 ± 0.461
SecondaryPart 2: Change From Baseline in Heart Rate

Vital signs including heart rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

Time frame:
Baseline and Up to Day 104
Reported as:
Mean · Beats per minute
Part 2: Change From Baseline in Heart Rate
Beats per minutePart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline in Heart Rate-4.2 ± 8.59-2.1 ± 7.86
SecondaryPart 2: Change From Baseline in ECG Parameters

12-lead ECG measurements was obtained using an ECG machine that automatically calculates the PR interval, QRS duration, QT interval and QTcB. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

Time frame:
Baseline and Up to Day 104
Reported as:
Mean · milliseconds
Part 2: Change From Baseline in ECG Parameters
millisecondsPart 2: TB006 1000 mg qwPart 2: Placebo
PR Interval-1.6 ± 13.172.1 ± 18.32
QRS Duration-2.2 ± 13.31-1.4 ± 7.71
QT Interval4.2 ± 26.293.9 ± 20.28
QTcB Interval-2.0 ± 18.01-1.7 ± 15.99
SecondaryPart 2: Change From Baseline in ECG Mean Heart Rate

12-lead ECG measurements was obtained using an ECG machine that automatically calculates the heart rate. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

Time frame:
Baseline and Up to Day 104
Reported as:
Mean · Beats per minute
Part 2: Change From Baseline in ECG Mean Heart Rate
Beats per minutePart 2: TB006 1000 mg qwPart 2: Placebo
Part 2: Change From Baseline in ECG Mean Heart Rate-1.8 ± 8.87-1.3 ± 7.40
SecondaryPart 2: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS

The C-SSRS is an interview-based instrument to systematically assess suicidal ideation and suicidal behavior. Number of participants that have an affirmative response to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 5 items for suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide) were reported. The total score ranges from 0 (no ideation present) to 5 (active suicidal ideation with specific plan and intent); higher scores indicate worse symptoms.

Time frame:
Up to Day 104
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS
ParticipantsPart 2: TB006 1000 mg qwPart 2: Placebo
Wish to be dead00
Non-specific active suicidal thoughts00
Active suicidal ideation without any methods without intent to act00
Active suicidal ideation with some intent to act, without specific plan00
Active suicidal ideation with specific plan and intent00
Any suicidal behavior00
Actual attempt00
Interrupted attempt00
Aborted attempt00
Preparatory acts or behavior00
Most recent attempt00
First attempt00
Lethal attempt00
SecondaryPart 2: Number of Participants With Clinically Significant Physical Examination Findings

A complete physical examination included, at a minimum, assessment of the Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.

Time frame:
Up to Day 104

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Clinically Significant Neurological Examination Findings

The neurological examination assessed mental status, motor and sensory skills, hearing and speech, vision, coordination, and balance. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.

Time frame:
Up to Day 104

No measurements were reported for this outcome.

SecondaryPart 2: Ctrough of TB006

Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

Time frame:
Day 29
Reported as:
Geometric mean · micrograms per milliliter
Part 2: Ctrough of TB006
micrograms per milliliterPart 2: TB006 1000 mg qw
Part 2: Ctrough of TB006395.82 ± 35.88
SecondaryPart 2: t1/2 of TB006

Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

Time frame:
Day 29
Reported as:
Geometric mean · hours
Part 2: t1/2 of TB006
hoursPart 2: TB006 1000 mg qw
Part 2: t1/2 of TB006756.78 ± 22.05
SecondaryPart 2: Cmax of TB006

Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

Time frame:
Day 1 and Day 29
Reported as:
Geometric mean · Micrograms per milliliter
Part 2: Cmax of TB006
Micrograms per milliliterPart 2: TB006 1000 mg qw
Day 1339.17 ± 23.82
Day 29731.55 ± 25.13

Adverse events

Collected over Up to Day 104. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: TB006 140 Milligrams (mg) Weekly (qw)0/7 (0%)1/7 (14.3%)5/7 (71.4%)
Part 1: TB006 420 mg qw0/6 (0%)0/6 (0%)4/6 (66.7%)
Part 1: TB006 1000 mg qw0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1: Placebo0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 2: TB006 1000 mg qw1/63 (1.6%)4/63 (6.3%)28/63 (44.4%)
Part 2: Placebo0/66 (0%)1/66 (1.5%)17/66 (25.8%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: PlaceboPart 2: TB006 1000 mg qwPart 2: Placebo
GastroenteritisInfections and infestations1/70/60/60/60/630/66
Atrial fibrillationCardiac disorders0/70/60/60/61/630/66
CholelithiasisHepatobiliary disorders0/70/60/60/61/630/66
Clostridium difficile colitisInfections and infestations0/70/60/60/61/630/66
PneumoniaInfections and infestations0/70/60/60/61/630/66
SepsisInfections and infestations0/70/60/60/61/630/66
HyponatraemiaMetabolism and nutrition disorders0/70/60/60/61/630/66
OsteoarthritisMusculoskeletal and connective tissue disorders0/70/60/60/61/630/66
RhabdomyolysisMusculoskeletal and connective tissue disorders0/70/60/60/61/630/66
Metabolic encephalopathyNervous system disorders0/70/60/60/61/630/66
Most frequent other events
Showing 10 of 63
Most frequent other events
EventPart 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: PlaceboPart 2: TB006 1000 mg qwPart 2: Placebo
Urinary tract infectionInfections and infestations0/72/60/60/63/631/66
Atrial fibrillationCardiac disorders0/70/61/60/61/630/66
Abdominal pain upperGastrointestinal disorders0/71/60/60/60/630/66
ProctitisGastrointestinal disorders0/71/60/60/60/630/66
Blood urea increasedInvestigations1/71/60/60/60/630/66
Blood creatinine increasedInvestigations0/71/60/60/62/631/66
Blood glucose increasedInvestigations0/70/60/61/60/630/66
Glycosylated haemoglobin increasedInvestigations0/70/60/61/60/630/66
Urine analysis abnormalInvestigations0/70/60/61/60/631/66
DizzinessNervous system disorders0/71/60/60/61/630/66

Baseline characteristics

Safety Analysis Set comprised of all participants randomly assigned to study drug and who took at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)Part 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: PlaceboPart 2: TB006 1000 mg qwPart 2: PlaceboTotal
Mean72.3 ± 3.2573.0 ± 10.4171.5 ± 6.7772.2 ± 6.7473.5 ± 9.3071.5 ± 7.6572.2 ± 7.35
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: PlaceboPart 2: TB006 1000 mg qwPart 2: PlaceboTotal
Female6425333686
Male1241303068
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: PlaceboPart 2: TB006 1000 mg qwPart 2: PlaceboTotal
Hispanic or Latino0153273975
Not Hispanic or Latino7513352677
Unknown or Not Reported0000112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: TB006 140 Milligrams (mg) Weekly (qw)Part 1: TB006 420 mg qwPart 1: TB006 1000 mg qwPart 1: PlaceboPart 2: TB006 1000 mg qwPart 2: PlaceboTotal
American Indian or Alaska Native0000000
Asian1000102
Native Hawaiian or Other Pacific Islander0000000
Black or African American11014613
White55655760138
More than one race0000000
Unknown or Not Reported0000101
08

Study locations

18 sites
  • Clinical Trial Site
    Garden Grove, California 92845, United States
  • Clinical Trial Site
    San Diego, California 92103, United States
  • Clinical Trial Site
    Delray Beach, Florida 33445, United States
  • Clinical Trial Site
    Lady Lake, Florida 32159, United States
  • Clinical Trial Site #1
    Maitland, Florida 32751, United States
  • Clinical Trial Site
    Maitland, Florida 32751, United States
  • Clinical Trial Site
    Miami, Florida 33126, United States
  • Clinical Trial Site
    Miami, Florida 33135, United States
  • Clinical Trial Site
    Miami, Florida 33137, United States
  • Clinical Trial Site
    Miami, Florida 33165, United States
  • Clinical Trial Site
    Stuart, Florida 34997, United States
  • Clinical Trial Site
    West Palm Beach, Florida 33407, United States
  • Clinical Trial Site
    Winter Park, Florida 32789, United States
  • Clinical Trial Site
    Winter Park, Florida 32792, United States
  • Clinical Trial Site
    Decatur, Georgia 30033, United States
  • Clinical Trial Site
    Matthews, North Carolina 28105, United States
  • Clinical Trial Site
    DeSoto, Texas 75115, United States
  • Clinical Trial Site
    Fairfax, Virginia 22031, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Oct 2022, 12 months.

Results were first posted in Nov 2023, 1 year 1 month after primary completion.

Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2021
First posted
Oct 12, 2021
StartActual
Oct 8, 2021
Primary completionActual
Oct 13, 2022
CompletionActual
Oct 13, 2022
Results first posted
Nov 18, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05074498
Lead sponsor
TrueBinding, Inc.
Responsible party
Sponsor
First posted
Oct 12, 2021
Start date
Oct 8, 2021
Primary completion
Oct 13, 2022
Completion
Oct 13, 2022
Results posted
Nov 18, 2023
Last update
Nov 18, 2023

Study contacts

TrueBinding, Inc.
study director · TrueBinding, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TB006

Start the discussion